The case for & against
Bull & Bear analysis
Bullish
International Flavors & Fragrances Inc. (NYSE: IFF) is a leading player in the flavor and fragrance industry, providing innovative solutions to a broad array of sectors, including food and beverage, personal care, and home solutions. The company is strategically repositioning itself towards health and biosciences, taste, and scent segments as it navigates market volatility while maintaining a focus on innovation and sustainability.
Bull says
- ↑Q1 revenue reached $2.7B, +3% YoY on broad volume growth
- ↑Free cash flow improved to $92M, up 144% YoY
- ↑Returned $137M via dividends and buybacks year-to-date
- ↑Reaffirmed 2026 guidance: $10.5–10.8B sales and $2.05–2.15B EBITDA
- ↑High earnings and dividend yields; book-to-price under 1 suggests undervaluation
- ↑Manageable debt levels support growth and strategic investments
Bear says
- ↓Health & biosciences unit sees expected negative growth in Q3
- ↓Energy and logistics cost inflation could pressure operating margins
- ↓Divestiture strategy carries execution risk and value-creation uncertainty
- ↓Earnings quality concerns amid negative profitability revisions and weak margins
- ↓High sensitivity to interest rates and oil prices raises macro volatility risk
- ↓Recent weak momentum and low quality score may deter investors
Investment themes with IFF
High Dividend Yield↑ +0.32%
Companies paying above-average dividends
AVGO · JPM · XOM
Earnings Call · Q1 2026 · Mgmt. Guidance
Updated 05-09-2026neutral
Transcript signals
Bull points
- In scent, I think we've got a very strong position in fine fragrance. We've got some temporary issues we're working through that we discussed. Consumer fragrance, we've got a very strong team there with a very good pipeline. And then we've got an R&D machine that's really picked up in the last year that takes 18 to 24 months to deliver. But we're seeing the progress in that pipeline that we'll deliver in 2027 that we're very excited about.
- As you recall, in 23, we had 9% EBITDA margin. 24, they built it to 12% EBITDA margin. 25, 13%. And then this year, I think we'll exceed 14% EBITDA margin. And that continues to grow and see more opportunity there. As we said before, as the portfolio was optimized within that organization and focusing on the higher growth opportunity areas. We've seen a return to top line growth there that we expect for the full year.
- a meaningful improvement in cash flow, really driven by improvements in profitability, improvement in working capital, lower interest expense, and a lower incentive compensation payout year over year versus prior year, so that's a favorability.
Bear points
- So I wouldn't expect that on a go-forward basis, and it will normalize.
- In Q2, we expect EBITDA to be lower than our Q1 performance. That's what I said in my prepared remarks. And when I think about it, there's probably three drivers. One, we expect growth to be more moderate in Q2 versus it was in Q1. We also expect to have a bit of an unfavorability in terms of price to input cost. As we talked about, we're seeing energy and logistic charges rising, and we haven't really fully implemented our surcharges in place yet, and that will happen over the course of the quarter. And so that will create a bit of a margin pressure in terms of where we are.
- The area of challenge that we've talked about is the health area. I'm pleased with the progress we're making to turn that around, but it still needs addressing.
Read full transcript analysis ›